Standardization of flow cytometry in myelodysplastic syndromes: report from the first European LeukemiaNet working conference on flow cytometry in myelodysplastic syndromes

AA van de Loosdrecht, C Alhan, MC Bene, MG Della Porta, AM Drager, J Feuillard, P Font, U Germing, D Haase, CH Homburg, R Ireland, JH (Joop) Jansen, W Kern, L Malcovati, Jeroen te Marvelde, GJ Mufti, K Ogata, A Orfao, GJ Ossenkoppele, A PorwitFW Preijers, SJ Richards, GJ Schuurhuis, D Subira, P Valent, Vincent van der Velden, P Vyas, AH Westra, TM de Witte, DA Wells, MR Loken, TM Westers

Research output: Contribution to journalArticleAcademicpeer-review

212 Citations (Scopus)
18 Downloads (Pure)


The myelodysplastic syndromes are a group of clonal hematopoietic stem cell diseases characterized by cytopenia(s), dysplasia in one or more cell lineages and increased risk of evolution to acute myeloid leukemia (AML). Recent advances in immunophenotyping of hematopoietic progenitor and maturing cells in dysplastic bone marrow point to a useful role for multiparameter Row cytometry (FCM) in the diagnosis and prognostication of myelodysplastic syndromes. In March 2008, representatives from 18 European institutes participated in a European LeukemiaNet (ELN) workshop held in Amsterdam as a first step towards standardization of FCM in myelodysplastic syndromes. Consensus was reached regarding standard methods for cell sampling, handling and processing. The group also defined minimal combinations of antibodies to analyze aberrant immunophenotypes and thus dysplasia. Examples are altered numbers of CD34(+) precursors, aberrant expression of markers on myeloblasts, maturing myeloid cells, monocytes or erythroid precursors and the expression of lineage infidelity markers. When applied in practice, aberrant FCM patterns correlate well with morphology, the subclassification of myelodysplastic syndromes, and prognostic scoring systems. However, the group also concluded that despite strong evidence for an impact of FCM in myelodysplastic syndromes, further (prospective) validation of markers and immunophenotypic patterns are required against control patient groups as well as further standardization in multi-center studies. Standardization of FCM in myelodysplastic syndromes may thus contribute to improved diagnosis and prognostication of myelodysplastic syndromes in the future.
Original languageUndefined/Unknown
Pages (from-to)1124-1134
Number of pages11
Issue number8
Publication statusPublished - 2009

Research programs

  • EMC MM-02-72-03

Cite this